Europe
Biopharma and life sciences companies from around the globe provide updates on their pipelines and businesses.
The Foundation will offer funding for development of the therapy.
In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses.
AstraZeneca Chief Executive Officer Pascal Soriot is seeing a significant return on the fruits of his company’s labor in 2020. Soriot’s annual compensation jumped a bit from the previous year to $21.4 million.
Centessa Pharmaceuticals, based in Cambridge, Massachusetts and London, launched what it is calling a “novel asset-centric pharmaceutical company.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
The WHO’s Emergency Use Listing (EUL), a prerequisite for COVAX Facility vaccine supply, evaluates the safety, quality, and efficacy of the COVID-19 vaccines. As such, today’s approval allows the vaccine to be used by agencies and NGOs around the world.
Biotech investor Neil Woodford is poised for a comeback after a fall from grace two years ago.
Early results from University of Oxford’s RECOVERY trial showed Roche’s immunosuppressant Actemra reduced deaths and the need for mechanical ventilation in severe COVID patients.
With billions invested in R&D over the past year to find vaccines and therapies for the novel coronavirus, a few select life sciences companies and academic institutions are working on the hypothesis that intranasal vaccines and therapies could be key to stopping COVID-19 in its tracks, and provide greater protection against transmission of COVID-19.
PRESS RELEASES